FOI release

Request for Clinical Overview and Public Assessment Report (PAR) for Doxazosin 8 mg Tablet

Some or all of the information requested may not have been provided because we determined that the request was vexatious.

Case reference FOI2026/00152

Received 13 February 2026

Published 23 March 2026

Request

Dear MHRA, We are in the process of developing a generic product of Doxazosin 8 mg Tablets. To support our assessment, we kindly request the Clinical Overview and Public Assessment Report (PAR) for the following Marketing Authorisation Holders. The agency website currently provides only the SPC and PIL information, which we have attached for the agency’s reference. 1. Product Name: Doxazosin 8 mg Tablets MAH: Milpharm Limited, UK MA No.: PL 16363/0291 Request: Clinical Overview and PAR 2. Product Name: Doxazosin Tablets 8 mg MAH: Ennogen IP Ltd, UK MA No.: PL 55612/0034 Request: Clinical Overview and PAR We would appreciate your assistance in providing these documents at your earliest convenience.

Response

See attached

Documents

• FOI2026_00152 (redacted).pdf (940.6 KB)

This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.